<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id><journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id><journal-title-group><journal-title>Orphanet Journal of Rare Diseases</journal-title></journal-title-group><issn pub-type="epub">1750-1172</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29471850</article-id><article-id pub-id-type="pmc">5824466</article-id><article-id pub-id-type="publisher-id">776</article-id><article-id pub-id-type="doi">10.1186/s13023-018-0776-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Zimran</surname><given-names>Ari</given-names></name><address><phone>972-509-149149</phone><email>azimran@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wajnrajch</surname><given-names>Michael</given-names></name><address><email>michael.wajnrajch@pfizer.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hernandez</surname><given-names>Betina</given-names></name><address><email>betina.hernandez@pfizer.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pastores</surname><given-names>Gregory M.</given-names></name><address><email>gpastores@mater.ie</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Gaucher Clinic, Shaare Zedek Medical Center, Hebrew University and Hadassah Medical School, 12 Bayit Street, P.O. Box 3235, 91031 Jerusalem, Israel </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8800 7493</institution-id><institution-id institution-id-type="GRID">grid.410513.2</institution-id><institution>Pfizer Inc, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0488 8430</institution-id><institution-id institution-id-type="GRID">grid.411596.e</institution-id><institution>University College Dublin and the National Centre for Inherited Metabolic Disorders, Mater Misericordiae University Hospital, </institution></institution-wrap>Dublin, Ireland </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><elocation-id>36</elocation-id><history><date date-type="received"><day>29</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>15</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Taliglucerase alfa is an enzyme replacement therapy (ERT) approved for treatment of adult and paediatric patients with Type 1 Gaucher disease (GD) in several countries and the first plant cell&#x02013;expressed recombinant therapeutic protein approved by the US Food and Drug Administration for humans. Here, we review the findings across six key taliglucerase alfa clinical studies. A total of 33 treatment-na&#x000ef;ve adult patients were randomized to taliglucerase alfa 30&#x000a0;U/kg or 60&#x000a0;U/kg in a 9-month, multicentre, randomized, double-blind, parallel-group, dose-comparison pivotal study, after which eligible patients continued into two consecutive extension studies; 17 treatment-na&#x000ef;ve adult patients completed 5 total years of treatment with taliglucerase alfa. In the only ERT study focused on exclusively paediatric patients with GD, 11 treatment-na&#x000ef;ve children were randomized to taliglucerase alfa 30&#x000a0;U/kg or 60&#x000a0;U/kg in a 12-month, multicentre, double-blind study; nine completed 3 total years of treatment in a dedicated paediatric extension study. The effect of switching patients from imiglucerase to taliglucerase alfa was also investigated in a separate 9-month study that included 26 adults and five children; 10 adults completed a total of 3&#x000a0;years and two children completed a total of 2.75&#x000a0;years of taliglucerase alfa treatment in the extension studies. All studies evaluated safety and spleen volume, liver volume, platelet count, haemoglobin concentration, and biomarkers as measures of efficacy. Detailed results from baseline through the end of these studies are presented. Taliglucerase alfa was well tolerated, and adverse events were generally mild/moderate in severity and transient. Treatment with taliglucerase alfa resulted in improvements (treatment-na&#x000ef;ve patients) or stability (patients switched from imiglucerase) in visceral, haematologic, and biomarker parameters. Together, this comprehensive data set supports the treatment of adult and paediatric patients with GD who are na&#x000ef;ve to ERT or who have previously been treated with imiglucerase.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Anaemia</kwd><kwd>Enzyme replacement therapy</kwd><kwd>Gaucher disease</kwd><kwd>Imiglucerase</kwd><kwd>Hepatomegaly</kwd><kwd>Paediatrics</kwd><kwd>Splenomegaly</kwd><kwd>Taliglucerase alfa</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par9">Gaucher disease (GD) is a rare lysosomal storage disorder caused by autosomal recessive mutations in the gene encoding &#x003b2;-glucocerebrosidase, a lysosomal enzyme required for the degradation of the glycolipid, glucocerebroside [<xref ref-type="bibr" rid="CR1">1</xref>]. The mutations cause deficiencies in &#x003b2;-glucocerebrosidase activity, resulting in lysosomal substrate accumulation of glucocerebroside within macrophages, which become engorged Gaucher cells and cause multisystemic damage in organs and tissues, including adverse effects on the spleen, liver, bone, platelets, and haemoglobin [<xref ref-type="bibr" rid="CR1">1</xref>]. There are three major types of GD [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]: Type 1 is the non-neuropathic and most prevalent form of the disease and can manifest at any age, from infancy to adulthood; Types 2 (acute) and 3 (sub&#x02013;acute) are neuropathic forms.</p><p id="Par10">For more than 2 decades, enzyme replacement therapy (ERT) has been the mainstay of treatment for patients with Type 1 GD [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>] and is highly effective in reversing the visceral and haematologic manifestations of the disease [<xref ref-type="bibr" rid="CR4">4</xref>]. In the United States and many countries in the European Union, three ERTs have been approved for the treatment of Type 1 GD: taliglucerase alfa, velaglucerase alfa, and imiglucerase. All three ERTs are recombinant active forms of &#x003b2;-glucocerebrosidase and are administered by intravenous infusion [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Both velaglucerase alfa and imiglucerase are produced in mammalian cell-based expression systems that require glycosylation modifications during production to expose the appropriate mannose residues needed for efficient cellular uptake of the recombinant enzymes, adding cost and additional steps to the production processes [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. Mammalian cell-based expression systems have also been vulnerable to the risk of supply shortage, such as the viral contamination of a bioreactor that prompted the temporary suspension of imiglucerase manufacturing [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par11">Taliglucerase alfa, the most recently approved ERT for Type 1 GD, was initially approved in 2012 by the US Food and Drug Administration for the treatment of Type 1 GD in adults [<xref ref-type="bibr" rid="CR8">8</xref>]. The US approval of taliglucerase alfa in adults was based on a phase 1 study performed in healthy volunteers, directly followed by two phase 3 studies&#x02014;one in na&#x000ef;ve adults and a second in ERT-experienced adults and children with Type 1 GD; there was a waiver obviating the need for a phase 2 study.</p><p id="Par12">Taliglucerase alfa was thus approved for use in both adult and paediatric populations with Type 1 GD in multiple countries including the United States and Canada, in adult patients with Type 1 GD in Panama, and for treatment of haematologic manifestations in paediatric patients with Type 3 GD in a number of countries, including Canada, Colombia, Ukraine, and Taiwan. Despite the drug&#x02019;s positive risk-benefit assessment, the European Medicines Agency recommended against marketing authorization for taliglucerase alfa in 2012 because velaglucerase alfa had received orphan market exclusivity in the European Union for Type 1 GD [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par13">Taliglucerase alfa is produced in carrot cells and is the first recombinant therapeutic protein produced in a plant cell-expression system to be approved for use in humans by the US Food and Drug Administration [<xref ref-type="bibr" rid="CR14">14</xref>]. The plant-based platform for producing taliglucerase alfa uses scalable, disposable bioreactors and is free of mammalian components [<xref ref-type="bibr" rid="CR11">11</xref>]. In addition, the production process for taliglucerase alfa does not require additional steps to create the glycan structures necessary for cellular uptake by Gaucher cells [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. The novel and unique features of the production process for taliglucerase alfa offer potential benefits regarding lack of mammalian contaminants (e.g., providing a natural firewall against mammalian infectious vectors), scalability, and cost benefits associated with disposable bioreactors and lack of need for additional steps to ensure correct glycosylation for efficient cellular uptake. The enzymatic activity of taliglucerase alfa and its uptake into macrophages have been shown to be comparable to those of imiglucerase, further supporting its place among available treatments for GD [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. The purpose of this review is to provide an overview of the results from the phase 3 clinical studies of taliglucerase alfa in adults and children with GD.</p><sec id="Sec2"><title>Overview of taliglucerase alfa phase 3 clinical studies</title><p id="Par14">Phase 3 clinical studies of taliglucerase alfa included adults &#x02265;18&#x000a0;years of age and children 2 to &#x0003c;&#x02009;18&#x000a0;years of age (combined: <italic>N</italic>&#x000a0;=&#x02009;73) who were either treatment-na&#x000ef;ve (adults: <italic>n</italic>&#x000a0;=&#x02009;31; children: <italic>n</italic>&#x000a0;=&#x02009;11) or switched from imiglucerase to taliglucerase alfa (adults: <italic>n</italic>&#x000a0;=&#x02009;26; children: <italic>n</italic>&#x000a0;=&#x02009;5). The flow of these studies is summarized in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, and patient disposition is summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The detailed methodology and patient flow have been described previously [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. A brief overview of the study designs, patient populations, treatments, and durations is provided in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Taliglucerase alfa phase 3 clinical studies</p></caption><graphic xlink:href="13023_2018_776_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient disposition in the taliglucerase alfa clinical studies<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient population and study</th><th>Enrolled</th><th>Completed</th><th>Notes</th></tr></thead><tbody><tr><td colspan="4">Adult treatment-naive patients</td></tr><tr><td>&#x02003;PB-06-001 [15]</td><td>33</td><td>29</td><td>&#x02022; 1 patient withdrew consent before first dose<break/>&#x02022; 3 patients discontinued</td></tr><tr><td>&#x02003;PB-06-003 [18]</td><td>26</td><td>23</td><td>&#x02022; 3 patients not recruited to PB-06-003<break/>&#x02022; 3 patients discontinued</td></tr><tr><td>&#x02003;PB-06-007 [21]</td><td>19</td><td>17</td><td>&#x02022; 4 patients not recruited into PB-06-007<break/>&#x02022; 2 patients discontinued</td></tr><tr><td colspan="4">Adult treatment-switched patients</td></tr><tr><td>&#x02003;PB-06-002 [16]</td><td>26</td><td>25</td><td>&#x02022; 1 patient discontinued</td></tr><tr><td>&#x02003;PB-06-003 [19]</td><td>19</td><td>10</td><td>&#x02022; 6 patients from PB-06-002 not recruited into PB-06-003,<break/> 5 of whom continued with compassionate use program<break/>&#x02022; 1 patient non-compliant<break/>&#x02022; 4 patients discontinued<break/>&#x02022; 4 patients treated for 30&#x02013;33 total months but transitioned to commercial use before study completion</td></tr><tr><td colspan="4">Paediatric treatment-na&#x000ef;ve patients</td></tr><tr><td>&#x02003;PB-06-005 [17]</td><td>11</td><td>11</td><td/></tr><tr><td>&#x02003;PB-06-006 [20]</td><td>10</td><td>9</td><td>&#x02022; 1 patient from PB-06-005 not recruited into PB-06-006 and continued with compassionate use program<break/>&#x02022; 1 patient dropped out during PB-06-006</td></tr><tr><td colspan="4">Paediatric treatment-switched patients</td></tr><tr><td>&#x02003;PB-06-002 [16]</td><td>5</td><td>5</td><td/></tr><tr><td>&#x02003;PB-06-006 [20]</td><td>5</td><td>4</td><td>&#x02022; 2 patients completed 27&#x000a0;months of treatment and continued with compassionate use program<break/>&#x02022; 2 patients completed 33&#x000a0;months of treatment<break/>&#x02022; 1 patient lost to follow-up</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>For full patient disposition details, refer to the original studies. For some endpoints, data were not available for all patients; refer to the original studies for reasons</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Overview of the taliglucerase alfa clinical studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study<sup>a</sup></th><th>Design</th><th>Patient population</th><th>
<italic>N</italic>
<sup>b</sup>
</th><th>Taliglucerase alfa<break/>treatment</th><th>Duration<break/>(Months)</th><th>Key efficacy findings</th><th>Key safety findings</th></tr></thead><tbody><tr><td>PB-06-001<break/>(NCT00376168)<break/>Zimran, 2011 [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>&#x02022; Multicentre<break/>&#x02022; Double-blind<break/>&#x02022; Randomized</td><td>&#x02022; Adults &#x02265;18&#x000a0;years<break/>&#x02022; Treatment-naive</td><td>31</td><td>&#x02022; Parallel dose<break/>&#x02022; 30&#x000a0;U/kg or 60&#x000a0;U/kg</td><td>9</td><td>&#x02022; Significant improvements in visceral and haematologic parameters and chitotriosidase activity</td><td>&#x02022; TEAEs mild/moderate and transient<break/>&#x02022; No SAEs</td></tr><tr><td>PB-06-002<break/>(NCT00712348)<break/>Pastores, 2014 [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td>&#x02022; Multicentre<break/>&#x02022; Open-label<break/>&#x02022; Switchover</td><td>&#x02022; Adults (<italic>n</italic>&#x000a0;=&#x02009;26) and children (<italic>n</italic>&#x000a0;=&#x02009;5) &#x000a0;&#x0003e;&#x02009;2&#x000a0;years<break/>&#x02022; Previously treated with imiglucerase</td><td>31</td><td>&#x02022; Same dose as previously treated with imiglucerase (9&#x02013;60&#x000a0;U/kg)</td><td>9</td><td>&#x02022; Stability of visceral, haematologic, and biomarker parameters</td><td>&#x02022; TEAEs mild/moderate and transient<break/>&#x02022; No SAEs related to treatment<break/>&#x02022; No discontinuations due to drug-related AEs</td></tr><tr><td>PB-06-003<break/>(NCT0070593)<break/>Zimran, 2016 [<xref ref-type="bibr" rid="CR18">18</xref>]; Pastores, 2016 [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td>&#x02022; Multicentre<break/>&#x02022; Double-blind and open-label<break/>&#x02022; Extension</td><td>&#x02022; Adults from PB-06-001 or PB-06-002<break/>&#x02022; Treatment-na&#x000ef;ve (<italic>n</italic>&#x000a0;=&#x02009;26) or treatment-switched (<italic>n</italic>&#x000a0;=&#x02009;19)</td><td>45</td><td>&#x02022; Same dose as in previous study</td><td>30</td><td>&#x02022; Treatment-na&#x000ef;ve: Visceral and biomarker parameters and platelets improved continuously; haemoglobin reached normal levels and stabilized<break/>&#x02022; Treatment-switched: Continued stability or improvement</td><td>&#x02022; TEAEs mild/moderate and transient<break/>&#x02022; All SAEs not related to treatment</td></tr><tr><td>PB-06-005<break/>(NCT01132690)<break/>Zimran, 2015 [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td>&#x02022; Multicentre<break/>&#x02022; Double-blind<break/>&#x02022; Randomized</td><td>&#x02022; Children 2&#x02013;&#x0003c;&#x02009;18&#x000a0;years<break/>&#x02022; Treatment-na&#x000ef;ve</td><td>11</td><td>&#x02022; Parallel dose<break/>&#x02022; 30&#x000a0;U/kg or 60&#x000a0;U/kg</td><td>12</td><td>&#x02022; Clinically significant improvements in visceral, haematologic, and biomarker parameters<break/>&#x02022; Trend toward improvement in exploratory parameters of growth and development<break/>&#x02022; Treatment well tolerated</td><td>&#x02022; Most AEs mild/moderate, transient, and not treatment-related<break/>&#x02022; No deaths<break/>&#x02022; No clinically meaningful laboratory abnormalities</td></tr><tr><td>PB-06-006<break/>(NCT01411228)<break/>Zimran, 2016 [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td>&#x02022; Multicentre<break/>&#x02022; Double-blind and open-label<break/>&#x02022; Extension</td><td>&#x02022; Children from PB-06-005 (originally treatment-na&#x000ef;ve; <italic>N</italic>&#x000a0;=&#x02009;10)<break/>&#x02022; Children from PB-06-002 (treatment-switched; <italic>N</italic>&#x000a0;=&#x02009;5)</td><td>15</td><td>&#x02022; Continued parallel doses at 30&#x000a0;U/kg or 60&#x000a0;U/kg<break/>&#x02022; Continued at previous dose in PB-06-002</td><td>24</td><td>&#x02022; Continued improvement (na&#x000ef;ve) or stability (switched) in visceral, haematologic, and biomarker parameters<break/>&#x02022; Continued improvement in exploratory parameters of growth and development<break/>&#x02022; Treatment well tolerated</td><td>&#x02022; All AEs mild/moderate<break/>&#x02022; No deaths<break/>&#x02022; No discontinuations due to AE<break/>&#x02022; No clinically meaningful laboratory abnormalities</td></tr><tr><td>PB-06-007<break/>(NCT01422187)<break/>Zimran, 2016 [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td>&#x02022; Multicentre<break/>&#x02022; Open-label<break/>&#x02022; Extension</td><td>&#x02022; Originally treatment-na&#x000ef;ve adults from PB-06-003</td><td>19</td><td>&#x02022; Continued parallel doses at 30&#x000a0;U/kg or 60&#x000a0;U/kg</td><td>21</td><td>&#x02022; Visceral and biomarker parameters and platelets improved continuously; haemoglobin remained stable</td><td>&#x02022; Most AEs mild/moderate and not treatment-related<break/>&#x02022; Most laboratory values normal</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Study PB-06-004 was an open-label expanded access study; results will be reported separately</p><p><sup>b</sup>Number of patients treated</p><p>AEs, adverse events; SAEs, serious adverse events; TEAEs, treatment-emergent adverse events</p></table-wrap-foot></table-wrap></p><p id="Par15">Primary and secondary efficacy end points included visceral (liver and spleen volume), haematologic (haemoglobin concentration, platelet count), and biomarker-related (chitotriosidase activity and/or chemokine C-C motif ligand 18 [CCL18 level]) parameters. Exploratory efficacy endpoints in the adult patients included changes in bone mineral density using dual-energy X-ray absorptiometry and a measurement of bone marrow fat fraction by quantitative chemical shift imaging [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Paediatric exploratory efficacy endpoints included changes in height, weight, growth velocity, puberty, and bone age based on radiographs of the left hand and wrist, and occurrence of bone events (including bone crises as part of the analysis of adverse events [AEs]), quality of life using the 28-item Child Health Questionnaire parent-report questionnaire for patients 5 to 18&#x000a0;years of age, and sexual development as assessed by Tanner staging [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Safety measurements in the clinical studies included AEs, immunogenicity (i.e., presence of anti-taliglucerase alfa IgG and IgE), assessment of neutralizing antibody activity using an in vitro assay and a cell-based assay, and assessment of infusion-associated reactions (i.e., hypersensitivity) [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Additional safety evaluations included physical examination, vital signs, and clinical laboratory assessments, as well as electrocardiogram, echocardiogram, and pulmonary function tests.</p></sec><sec id="Sec3"><title>Efficacy</title><p id="Par16">Key efficacy findings from the taliglucerase alfa phase 3 clinical studies are summarized in Table <xref rid="Tab2" ref-type="table">2</xref> [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], with additional efficacy results shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> (treatment-na&#x000ef;ve patients) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] and Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> (treatment-switched patients) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].<table-wrap id="Tab3"><label>Table 3</label><caption><p>Efficacy results for taliglucerase alfa in treatment-na&#x000ef;ve patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">Adults</th><th colspan="3">Children</th></tr><tr><th/><th colspan="2">PB-06-001 [15]<break/><italic>N</italic> = 32<sup>a</sup></th><th>PB-06-003 [18]<break/><italic>N</italic>&#x000a0;=&#x02009;26</th><th>PB-06-007 [21]<break/><italic>N</italic>&#x000a0;=&#x02009;19</th><th colspan="2">PB-06-005 [17]<break/><italic>N</italic>&#x000a0;=&#x02009;11</th><th>PB-06-006 [20]<break/><italic>N</italic>&#x000a0;=&#x02009;10</th></tr><tr><th>Parameter</th><th>Baseline</th><th>9&#x000a0;Months change from baseline<sup>b</sup></th><th>36&#x000a0;Months</th><th>60&#x000a0;Months</th><th>Baseline</th><th>12&#x000a0;Months</th><th>36&#x000a0;Months</th></tr></thead><tbody><tr><td colspan="8">Spleen volume, MN</td></tr><tr><td>&#x02003;30&#x000a0;U/kg</td><td>15 (<italic>n</italic>&#x000a0;=&#x02009;15)</td><td>&#x02212;26.9% (<italic>n</italic>&#x000a0;=&#x02009;15)</td><td>8.2 (<italic>n</italic>&#x000a0;=&#x02009;12)</td><td>6.6 (<italic>n</italic>&#x000a0;=&#x02009;7)</td><td>22.2 (<italic>n</italic>&#x000a0;=&#x02009;6)</td><td>14.0 (<italic>n</italic>&#x000a0;=&#x02009;6)</td><td>9.0 (<italic>n</italic>&#x000a0;=&#x02009;4)</td></tr><tr><td>&#x02003;60&#x000a0;U/kg</td><td>17 (<italic>n</italic>&#x000a0;=&#x02009;16)</td><td>&#x02212;38.0% (<italic>n</italic>&#x000a0;=&#x02009;16)</td><td>5.6 (<italic>n</italic>&#x000a0;=&#x02009;11)</td><td>3.2 (<italic>n</italic>&#x000a0;=&#x02009;7)</td><td>29.4 (<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>12.9 (<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>6.6 (<italic>n</italic>&#x000a0;=&#x02009;3)</td></tr><tr><td colspan="8">Liver volume, MN</td></tr><tr><td>&#x02003;30&#x000a0;U/kg</td><td>1.7 (<italic>n</italic>&#x000a0;=&#x02009;15)</td><td>&#x02212;10.5% (<italic>n</italic>&#x000a0;=&#x02009;14)</td><td>1.3 (<italic>n</italic>&#x000a0;=&#x02009;12)</td><td>1.2 (<italic>n</italic>&#x000a0;=&#x02009;7)</td><td>1.8 (<italic>n</italic>&#x000a0;=&#x02009;6)</td><td>1.5 (<italic>n</italic>&#x000a0;=&#x02009;6)</td><td>1.3 (<italic>n</italic>&#x000a0;=&#x02009;4)</td></tr><tr><td>&#x02003;60&#x000a0;U/kg</td><td>1.6 (<italic>n</italic>&#x000a0;=&#x02009;16)</td><td>&#x02212;11.1% (<italic>n</italic>&#x000a0;=&#x02009;15)</td><td>1.1 (<italic>n</italic>&#x000a0;=&#x02009;11)</td><td>1.0 (<italic>n</italic>&#x000a0;=&#x02009;7)</td><td>2.2 (<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>1.7 (<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>1.5 (<italic>n</italic>&#x000a0;=&#x02009;3)</td></tr><tr><td colspan="8">Haemoglobin, mg/dL</td></tr><tr><td>&#x02003;30&#x000a0;U/kg</td><td>12.2 (<italic>n</italic>&#x000a0;=&#x02009;15)</td><td>+&#x02009;1.6 (<italic>n</italic>&#x000a0;=&#x02009;14)</td><td>14.3 (<italic>n</italic>&#x000a0;=&#x02009;11)</td><td>14.1 (<italic>n</italic>&#x000a0;=&#x02009;7)</td><td>11.3 (<italic>n</italic>&#x000a0;=&#x02009;6)</td><td>12.7 (<italic>n</italic>&#x000a0;=&#x02009;6)</td><td>13.2 (<italic>n</italic>&#x000a0;=&#x02009;5)</td></tr><tr><td>&#x02003;60&#x000a0;U/kg</td><td>11.4 (<italic>n</italic>&#x000a0;=&#x02009;16)</td><td>+&#x02009;2.2 (<italic>n</italic>&#x000a0;=&#x02009;15)</td><td>14.0 (<italic>n</italic>&#x000a0;=&#x02009;11)</td><td>13.9 (<italic>n</italic>&#x000a0;=&#x02009;8)</td><td>10.6 (<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>12.2 (<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>12.7 (<italic>n</italic>&#x000a0;=&#x02009;4)</td></tr><tr><td colspan="8">Platelet count, /mm<sup>3</sup></td></tr><tr><td>&#x02003;30&#x000a0;U/kg</td><td>75,320 (<italic>n</italic>&#x000a0;=&#x02009;15)</td><td>+&#x02009;11,427 (<italic>n</italic>&#x000a0;=&#x02009;15)</td><td>94,683 (<italic>n</italic>&#x000a0;=&#x02009;12)</td><td>104,986 (<italic>n</italic>&#x000a0;=&#x02009;7)</td><td>162,667 (<italic>n</italic>&#x000a0;=&#x02009;6)</td><td>208,167 (<italic>n</italic>&#x000a0;=&#x02009;6)</td><td>220,020 (<italic>n</italic>&#x000a0;=&#x02009;5)</td></tr><tr><td>&#x02003;60&#x000a0;U/kg</td><td>65,038 (<italic>n</italic>&#x000a0;=&#x02009;16)</td><td>+&#x02009;41,494 (<italic>n</italic>&#x000a0;=&#x02009;16)</td><td>147,727 (<italic>n</italic>&#x000a0;=&#x02009;11)</td><td>180,625 (<italic>n</italic>&#x000a0;=&#x02009;8)</td><td>99,600 (<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>172,200 (<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>243,750 (<italic>n</italic>&#x000a0;=&#x02009;4)</td></tr><tr><td colspan="8">Chitotriosidase, percent change from baseline<sup>c</sup></td></tr><tr><td>&#x02003;30&#x000a0;U/kg</td><td>&#x02500;</td><td>&#x02212;&#x02009;47% (<italic>n</italic>&#x000a0;=&#x02009;14)</td><td>&#x02212;&#x02009;71.5% (<italic>n</italic>&#x000a0;=&#x02009;12)</td><td>&#x02212;83.1% (<italic>n</italic>&#x000a0;=&#x02009;7)</td><td>&#x02500;</td><td>&#x02212;&#x02009;58.5% (<italic>n</italic>&#x000a0;=&#x02009;6)</td><td>&#x02212;72.7 (<italic>n</italic>&#x000a0;=&#x02009;5)</td></tr><tr><td>&#x02003;60&#x000a0;U/kg</td><td>&#x02500;</td><td>&#x02212;58% (<italic>n</italic>&#x000a0;=&#x02009;15)</td><td>&#x02212;82.2% (<italic>n</italic>&#x000a0;=&#x02009;10)</td><td>&#x02212;93.4% (<italic>n</italic>&#x000a0;=&#x02009;7)</td><td>&#x02500;</td><td>&#x02212;66.1% (<italic>n</italic>&#x000a0;=&#x02009;4)</td><td>&#x02212;&#x02009;84.4 (<italic>n</italic>&#x000a0;=&#x02009;3)</td></tr><tr><td colspan="8">CCL18, percent change from baseline<sup>b</sup></td></tr><tr><td>&#x02003;30&#x000a0;U/kg</td><td>&#x02500;</td><td>NR<sup>d</sup></td><td>&#x02212;&#x02009;58.1% (<italic>n</italic>&#x000a0;=&#x02009;12)</td><td>&#x02212;66.7% (<italic>n</italic>&#x000a0;=&#x02009;7)</td><td>&#x02500;</td><td>NR<sup>d</sup></td><td>&#x02212;&#x02009;67.7% (<italic>n</italic>&#x000a0;=&#x02009;5)</td></tr><tr><td>&#x02003;60&#x000a0;U/kg</td><td>&#x02500;</td><td>NR<sup>d</sup></td><td>&#x02212;&#x02009;71.0% (<italic>n</italic>&#x000a0;=&#x02009;11)</td><td>&#x02212;83.3% (<italic>n</italic>&#x000a0;=&#x02009;8)</td><td>&#x02500;</td><td>NR<sup>d</sup></td><td>&#x02212;&#x02009;73.2% (<italic>n</italic>&#x000a0;=&#x02009;4)</td></tr></tbody></table><table-wrap-foot><p>Values represent means</p><p><sup>a</sup>32 patients were randomized; 31 received treatment</p><p><sup>b</sup>Absolute values at 9&#x000a0;months were not reported; percent change from baseline was reported for organ volumes and absolute change from baseline was reported for haematological parameters</p><p><sup>c</sup>To determine change from baseline for biomarkers, baseline values from entry into the original study (PB-06-001 for adults; PB-06-005 for children) were re-run at each time point due to high assay variability</p><p><sup>d</sup>Values are available for individual patients in the publications cited</p><p>CCL18, chemokine (C-C) motif ligand 18; MN, multiples of normal where normal spleen volume is 2&#x000a0;mL/kg &#x000d7; body weight (kg) and normal liver volume is 25&#x000a0;mL/kg &#x000d7; body weight (kg); NR, not reported</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>Efficacy results for taliglucerase alfa in treatment-switched patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Adults</th><th colspan="3">Children</th></tr><tr><th/><th colspan="2">PB-06-002 [<xref ref-type="bibr" rid="CR16">16</xref>]<break/><italic>N</italic>&#x000a0;=&#x02009;26</th><th>PB-06-003 [<xref ref-type="bibr" rid="CR19">19</xref>]<break/><italic>N</italic>&#x000a0;=&#x02009;10</th><th colspan="2">PB-06-002 [<xref ref-type="bibr" rid="CR16">16</xref>]<break/><italic>N</italic>&#x000a0;=&#x02009;5</th><th>PB-06-006 [<xref ref-type="bibr" rid="CR20">20</xref>]<break/><italic>N</italic>&#x000a0;=&#x02009;5</th></tr><tr><th>Parameter</th><th>Baseline</th><th>9&#x000a0;Months</th><th>33&#x000a0;Months, percent change from baseline<sup>a</sup></th><th>Baseline</th><th>9&#x000a0;Months</th><th>33&#x000a0;Months, percent change from baseline<sup>a</sup></th></tr></thead><tbody><tr><td>Spleen volume, MN</td><td>5.5<break/>(<italic>n</italic>&#x000a0;=&#x02009;20)</td><td>5.1<break/>(<italic>n</italic>&#x000a0;=&#x02009;20)</td><td>&#x02212;19.8%<break/>(<italic>n</italic>&#x000a0;=&#x02009;7)</td><td>4.1<break/>(<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>3.3<break/>(<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>&#x02212;5.3%<break/>(<italic>n</italic>&#x000a0;=&#x02009;2)</td></tr><tr><td>Liver volume, MN</td><td>1.0<break/>(<italic>n</italic>&#x000a0;=&#x02009;23)</td><td>0.9<break/>(<italic>n</italic>&#x000a0;=&#x02009;23)</td><td>No change<break/>(<italic>n</italic>&#x000a0;=&#x02009;8)</td><td>1.3<break/>(<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>1.2<break/>(<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>&#x02212;&#x02009;8.8%<break/>(<italic>n</italic>&#x000a0;=&#x02009;2)</td></tr><tr><td>Haemoglobin, mg/dL</td><td>13.5<break/>(<italic>n</italic>&#x000a0;=&#x02009;25)</td><td>Stable<break/>(<italic>n</italic>&#x000a0;=&#x02009;25)</td><td>&#x02212;1.0%<break/>(<italic>n</italic>&#x000a0;=&#x02009;10)</td><td>13.5<break/>(<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>Stable<break/>(<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>+&#x02009;3.3%<break/>(<italic>n</italic>&#x000a0;=&#x02009;2)</td></tr><tr><td>Platelet count, /mm<sup>3</sup></td><td>160,447<break/>(<italic>n</italic>&#x000a0;=&#x02009;25)</td><td>Stable<break/>(<italic>n</italic>&#x000a0;=&#x02009;25)</td><td>Nominal<break/>(<italic>n</italic>&#x000a0;=&#x02009;10)</td><td>164,587<break/>(<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>Stable<break/>(<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>+&#x02009;2.3%<break/>(<italic>n</italic>&#x000a0;=&#x02009;2)</td></tr><tr><td>Chitotriosidase, percent change from baseline<sup>b</sup></td><td>&#x02013;</td><td>&#x02212;&#x02009;21.3%<break/>(<italic>n</italic>&#x000a0;=&#x02009;23)</td><td>&#x02212;51.5%<break/>(<italic>n</italic>&#x000a0;=&#x02009;10)</td><td>&#x02013;</td><td>&#x02212;&#x02009;29.7%<break/>(<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>&#x02212;97.1%<break/>(<italic>n</italic>&#x000a0;=&#x02009;2)</td></tr><tr><td>CCL18, percent change from baseline<sup>b</sup></td><td>&#x02013;</td><td>Decrease<break/>(<italic>n</italic>&#x000a0;=&#x02009;23)</td><td>&#x02212;36.5%<break/>(<italic>n</italic>&#x000a0;=&#x02009;10)</td><td>&#x02013;</td><td>Decrease<break/>(<italic>n</italic>&#x000a0;=&#x02009;5)</td><td>&#x02212;10.8%<break/>(<italic>n</italic>&#x000a0;=&#x02009;2)</td></tr></tbody></table><table-wrap-foot><p>Values represent means</p><p><sup>a</sup>Absolute values at 33&#x000a0;months not reported; percent change from baseline reported</p><p><sup>b</sup>To determine change from baseline for biomarkers, baseline values from entry into the original study (PB-06-002) were re-run at each time point due to high assay variability</p><p>CCL18, chemokine (C-C) motif ligand 18; MN, multiples of normal where normal spleen volume is 2&#x000a0;mL/kg &#x000d7; body weight (kg) and normal liver volume is 25&#x000a0;mL/kg &#x000d7; body weight (kg)</p></table-wrap-foot></table-wrap></p><sec id="Sec4"><title>Treatment-na&#x000ef;ve adult patients with GD</title><p id="Par17">At the end of the 9-month treatment period of pivotal Study PB-06-001 (treatment-na&#x000ef;ve adult patients), all patients achieved the primary endpoint of reduction in spleen volume (30&#x000a0;U/kg: 26.9%; 60&#x000a0;U/kg: 38.0%; both <italic>P</italic>&#x000a0;&#x0003c;&#x02009;0.0001). In the 30&#x000a0;U/kg and 60&#x000a0;U/kg groups, respectively, significant reductions were also observed at 9&#x000a0;months versus baseline in liver volume (10.5%, <italic>P</italic>&#x000a0;=&#x02009;0.004, and 11.1%, <italic>P</italic>&#x000a0;&#x0003c;&#x02009;0.0001) and chitotriosidase activity (50% in both dose groups, <italic>P</italic>&#x000a0;&#x0003c;&#x02009;0.0001 and <italic>P</italic>&#x000a0;=&#x02009;0.0016), as well as a significant increase in haemoglobin concentration (1.6&#x000a0;g/dL, <italic>P</italic>&#x000a0;=&#x02009;0.001, and 2.2&#x000a0;g/dL, <italic>P</italic>&#x000a0;&#x0003c;&#x02009;0.0001). Platelet count increased significantly in the 60&#x000a0;U/kg group (41,494/mm<sup>3</sup>, <italic>P</italic>&#x000a0;=&#x02009;0.0031) and increased by 11,427/mm<sup>3</sup> in the 30&#x000a0;U/kg group but did not achieve the prespecified alpha of 0.025 [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par18">From baseline in original study PB-06-001 to the end of extension study PB-06-003 (up to 36 total months of treatment), taliglucerase alfa 30&#x000a0;U/kg and 60&#x000a0;U/kg, respectively, produced decreases in spleen volume (50.1% and 64.6%), liver volume (25.6% and 24.4%), chitotriosidase activity (71.5% and 82.2%), and CCL18 concentration (58.1% and 71.0%), and increases in haemoglobin concentration (16.0% and 35.8%) and platelet count (45.7% and 114.0%) [<xref ref-type="bibr" rid="CR20">20</xref>]. At the end of adult extension study PB-06-007 (60 total months of treatment), the 30&#x000a0;U/kg, 60&#x000a0;U/kg, and dose-adjusted groups, respectively, demonstrated reductions in spleen volume (56.7%, 57.9%, and 61.0%), liver volume (32.5%, 23.3%, and 30.4%), chitotriosidase activity (83.1%, 93.4%, and 87.9%), and CCL18 concentration (66.7%, 83.3%, and 78.9%), and increases in haemoglobin concentration (2.1, 2.1, and 1.8&#x000a0;mg/dL) and platelet count (31,871, 106,800, and 34,000/mm<sup>3</sup>) versus PB-06-001 baseline [<xref ref-type="bibr" rid="CR21">21</xref>]. In PB-06-007, lumbar spine fat fraction was assessed in a subset of patients, and clinically meaningful improvements occurred for this exploratory endpoint [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec5"><title>Treatment-switched adult patients with GD</title><p id="Par19">Overall at the end of the 9-month treatment period in Study PB-06-002, disease parameters remained stable in patients who were previously treated with imiglucerase and switched to the same dose of taliglucerase alfa. Reductions were observed in spleen volume (7.6%), liver volume (3.5%), chitotriosidase activity (21.3%), and CCL18 concentration (value not reported) compared with baseline [<xref ref-type="bibr" rid="CR16">16</xref>]. One adult patient had an increase in spleen volume, and one adult and one paediatric patient had increases in liver volume; these increases were not considered clinically meaningful and none of these patients experienced clinically relevant deteriorations in other efficacy parameters. One patient met the clinical protocol criteria for a sustained clinical deterioration in platelet count but improved to a platelet count of 170,000/mm<sup>3</sup> by month 9 of treatment. Treatment-switched adult patients who had previously been in PB-06-002 generally demonstrated clinical stability for up to 36 total months in extension study PB-06-003, as evidenced by unchanged haemoglobin concentration, platelet count, and liver volume as well as reductions in spleen volume (19.8%), chitotriosidase activity (51.5%), and CCL18 concentration (36.5%) compared with baseline in original study PB-06-001 [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec6"><title>Treatment-na&#x000ef;ve paediatric patients with GD</title><p id="Par20">At the end of the 12-month study of treatment-na&#x000ef;ve paediatric patients (PB-06-005), median percent changes (increases) in haemoglobin concentration (primary endpoint) were 12.2% for 30&#x000a0;U/kg and 14.2% for 60&#x000a0;U/kg (mean percent increases were 13.8% and 15.8%, respectively) [<xref ref-type="bibr" rid="CR17">17</xref>]. From baseline to month 12, improvements were observed with decreases in absolute spleen volume in the 30&#x000a0;U/kg and 60&#x000a0;U/kg groups, respectively, of 28.6% and 41.1% and liver volume of 6.3% and 14.0%, as well as increases in platelet count of 30.9% and 73.7%, and decreases in chitotriosidase activity of 58.5% and 66.1% [<xref ref-type="bibr" rid="CR17">17</xref>]. Analyses of exploratory endpoints for growth and development also trended toward improvement [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par21">By the end of the paediatric extension study (PB-06-006), the patients who were previously in PB-06-005 (treatment-na&#x000ef;ve paediatric patients) had received up to 36 total months of treatment. Patients in the 30&#x000a0;U/kg and 60&#x000a0;U/kg groups, respectively, achieved reductions in mean spleen volume (18.6 multiples of normal [MN] and 26.0 MN), liver volume (0.8 MN and 0.9 MN), and chitotriosidase activity (72.7% and 84.4%), and increases in haemoglobin concentrations (2.0&#x000a0;g/dL and 2.3&#x000a0;g/dL) and platelet counts (38,200/mm<sup>3</sup> and 138,250/mm<sup>3</sup>) compared with baseline. Improvement in chitotriosidase and CCL18 continued through 36 total months of treatment, with most improvement noted by month 12 [<xref ref-type="bibr" rid="CR20">20</xref>]. In treatment-na&#x000ef;ve paediatric patients enrolled in PB-06-006, height increased by 12.4% (30&#x000a0;U/kg) and 19.2% (60&#x000a0;U/kg). Height velocity was 5.5&#x000a0;cm/year (30&#x000a0;U/kg) and 6.7&#x000a0;cm/year (60&#x000a0;U/kg). Weight increased by 39.8% (30&#x000a0;U/kg) and 35.0% (60&#x000a0;U/kg). Overall, eight of the 10 treatment-na&#x000ef;ve paediatric patients had no change in pubertal status, as assessed by Tanner staging, while one patient progressed from Tanner stage 1 at baseline to stage 3 by the end of PB-06-006, and another patient advanced from Tanner stage 3 to stage 4 by 18&#x000a0;months. Over the 36-month trial period, bone age advanced by 3.6&#x000a0;years (30&#x000a0;U/kg) and 4.6&#x000a0;years (60&#x000a0;U/kg). In quality-of-life assessments, the number of parents/caregivers who rated their children&#x02019;s global health as &#x0201c;very good&#x0201d; was greater at 36&#x000a0;months than at baseline [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec7"><title>Treatment-switched paediatric patients with GD</title><p id="Par22">At the end of the 9-month treatment period of PB-06-002, all five children in the study remained clinically stable after being switched from imiglucerase to the same dose of taliglucerase alfa. Haemoglobin concentration and platelet concentration were unchanged, and reductions were observed in spleen volume (6.6%), liver volume (baseline: 1.3 MN; month 9: 1.2 MN), and chitotriosidase activity (29.7%) compared with baseline [<xref ref-type="bibr" rid="CR16">16</xref>]. Treatment-switched paediatric patients from PB-06-002 who continued taliglucerase treatment in PB-06-006 maintained clinical stability. From baseline to up to 33&#x000a0;months, values remained stable or improved for spleen volume, haemoglobin concentration, platelet count, liver volume, chitotriosidase activity, and CCL18 concentration [<xref ref-type="bibr" rid="CR20">20</xref>]. Exploratory growth and developmental endpoints of height and weight increased by 5.0% and 18.2%, respectively, and height velocity increased by 2.5&#x000a0;cm/year in treatment-switched paediatric patients [<xref ref-type="bibr" rid="CR20">20</xref>]. Bone age increased by 2.3&#x000a0;years. Quality of life was not assessed in treatment-switched paediatric patients [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec></sec><sec id="Sec8"><title>Safety and immunogenicity</title><sec id="Sec9"><title>Treatment-na&#x000ef;ve and treatment-switched adult patients</title><p id="Par23">In PB-06-001 (treatment-na&#x000ef;ve adult patients), no serious AEs were observed. The most frequently experienced treatment-related AEs were headache and pruritus. Two patients discontinued from the study due to a hypersensitivity reaction, and two patients developed anti-taliglucerase alfa antibodies that were determined to be non-neutralizing [<xref ref-type="bibr" rid="CR15">15</xref>]. The most common AEs in extension study PB-06-003 (treatment-na&#x000ef;ve adult patients) were arthralgia, headache, upper respiratory tract infection, pain in extremity, nasopharyngitis, and hypertension. Most (98.5%) AEs and all treatment-related AEs were mild or moderate in severity and transient in nature. Thirteen patients were found to have anti-taliglucerase alfa antibodies on at least one post-baseline visit; two of these patients were found to have neutralizing antibodies, but efficacy did not appear to be impaired by the development of neutralizing antibodies [<xref ref-type="bibr" rid="CR18">18</xref>]. In Study PB-06-003 [<xref ref-type="bibr" rid="CR18">18</xref>], the numbers of patients reported to develop anti-taliglucerase alfa IgG antibodies were higher than those reported in previous, shorter term studies [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. This was likely attributable to increased assay sensitivity due to assay modifications that resulted in differences in antibody sample positivity reporting. The assay modifications were made to establish statistically based cut-point definitions consistent with industry practices.</p><p id="Par24">In extension study PB-06-007 (treatment-na&#x000ef;ve adult patients), taliglucerase alfa was well tolerated. The most common AEs were nasopharyngitis and arthralgia. None of the AEs were related to treatment or led to study withdrawal, and 97.3% of the AEs were mild or moderate in severity. One patient who experienced hypersensitivity during PB-06-003 did not receive pre-medication and did not have a recurrence during PB-06-007. Eight patients had previously tested positive for anti-taliglucerase alfa antibodies before entry into PB-06-007. Five of those patients had also tested positive in PB-06-007, but did not discontinue and had no new treatment-related AEs. Three of the five patients tested positive for neutralizing activity using an in vitro assay [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par25">In PB-06-002 (treatment-switched adult patients), the most frequent AEs reported in the adult patients were infusion-related reaction and nasopharyngitis. None of the severe or serious AEs were considered related to treatment. No discontinuations were due to a treatment-related AE, and all treatment-related AEs were mild or moderate in severity and transient in nature. Three patients tested positive for anti-taliglucerase IgG antibodies at some point during the study, including screening. Two of the patients were negative for neutralizing antibodies in the in vitro and cell-based assays, and neither experienced any treatment-related AEs. The third patient tested positive only in the in vitro assay [<xref ref-type="bibr" rid="CR16">16</xref>]. In extension study PB-06-003 (treatment-switched adult patients), the most common AEs were nasopharyngitis, pyrexia, arthralgia, diarrhoea, vomiting, upper respiratory tract infection, cough, and musculoskeletal pain. Most AEs and all treatment-related AEs were mild or moderate in severity and transient in nature. Among the treatment-switched patients in PB-06-003, a total of four tested positive for anti-taliglucerase alfa IgG antibodies, including one patient who had evidence of neutralizing activity in an in vitro assay but who had a negative cell-based assay [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec10"><title>Treatment-na&#x000ef;ve and treatment-switched paediatric patients</title><p id="Par26">In PB-06-005 (treatment-na&#x000ef;ve paediatric patients), most AEs were mild or moderate in severity, transient in nature, and not related to treatment. None of the AEs led to study withdrawal. One serious treatment-related AE (gastroenteritis requiring hospitalization for rehydration) occurred in a patient receiving taliglucerase alfa 60&#x000a0;U/kg during the first infusion visit; the incidence resolved after 1&#x000a0;day. None of the patients were diagnosed with a GD-related bone crisis during the study or experienced treatment-related bone pain. Three patients were positive for anti-taliglucerase alfa antibodies; all three patients had low titres, tested negative for neutralizing antibodies, continued to improve in GD parameters during the study with no apparent effect on efficacy and safety, and completed the study [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par27">All AEs in PB-06-002 (treatment-switched paediatric patients) were considered mild or moderate in severity and unrelated to treatment. No severe AEs were reported in paediatric patients, and no children discontinued the study due to a drug-related AE. Anti-taliglucerase alfa antibodies were detected in two paediatric patients before treatment began and early on thereafter but not at later time points; both tested negative for the presence of neutralizing antibodies in the in vitro assay [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par28">In extension study PB-06-006, which encompassed treatment-na&#x000ef;ve paediatric patients from PB-06-005 and treatment-switched paediatric patients from PB-06-002, all AEs were mild or moderate in severity and none led to change in taliglucerase alfa dose or study discontinuation. The most common AEs were cough, headache, upper respiratory tract infection, abdominal pain, Dengue fever, diarrhoea, lymphedema, nasopharyngitis, and extremity pain. One AE was possibly related to treatment (mild Grade 1 infusion site pain in a treatment-na&#x000ef;ve patient), but it resolved on the same day and was considered non-serious. One serious AE (Grade 2 Dengue fever) was reported in a treatment-na&#x000ef;ve paediatric patient; the child was hospitalized and the event resolved within 5&#x000a0;weeks. No bone crises occurred during the study. One treatment-na&#x000ef;ve paediatric patient who tested positive for anti-taliglucerase alfa IgG antibodies in PB-06-005 remained antibody-positive through PB-06-006 and tested positive for neutralizing antibodies based on the in vitro enzymatic activity assay; however, the child continued to show improvements in spleen and liver volumes, haemoglobin levels, platelet counts, chitotriosidase activity, and CCL18 levels through the 36 total months of taliglucerase alfa treatment. All paediatric patients in PB-06-006 who switched from imiglucerase tested negative for anti-taliglucerase alfa IgG antibodies during the extension study [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec></sec><sec id="Sec11"><title>Pharmacokinetics</title><p id="Par29">The characterization of taliglucerase alfa pharmacokinetics (PK) was based on samples from 26 of the 31 patients in the pivotal PB-06-001 study (treatment-na&#x000ef;ve adult patients) and 10 of the 15 patients in PB-06-006 (treatment-na&#x000ef;ve and treatment-switched paediatric patients) [<xref ref-type="bibr" rid="CR22">22</xref>]. Single-dose PK in adults were based on day 1 serial blood samples and multiple-dose PK were based on week 38 samples [<xref ref-type="bibr" rid="CR22">22</xref>]. Multiple-dose PK in paediatric patients were based on samples collected after 10 to 27&#x000a0;months of treatment.</p><p id="Par30">In adults and children, the 60&#x000a0;U/kg dose resulted in higher exposure (as measured by maximum plasma concentration, area under the plasma concentration-versus-time curve from time zero to the last measured concentration, and area under the plasma concentration-versus-time curve from time zero to infinity) than the 30&#x000a0;U/kg dose [<xref ref-type="bibr" rid="CR22">22</xref>]. Within the adult and paediatric patient populations, the two dose groups were similar in mean time of maximum plasma concentration and elimination half-life values for taliglucerase alfa [<xref ref-type="bibr" rid="CR22">22</xref>]. No tendency for accumulation or change in taliglucerase alfa PK was observed after repeated infusion with either dose over 38&#x000a0;weeks in adult patients [<xref ref-type="bibr" rid="CR22">22</xref>]. Furthermore, dose-normalized exposure was comparable between adult and paediatric patients and showed dose proportionality in paediatric patients [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par31">Treatment with taliglucerase alfa across six phase 3 clinical studies in treatment-na&#x000ef;ve or treatment-switched adult and paediatric patients has been shown to result in clinically and statistically significant improvements in the major clinical features of Type I GD. Across these studies, taliglucerase alfa was well tolerated. Long-term improvements were observed in major GD disease parameters and biomarkers in treatment-na&#x000ef;ve adult patients at dose levels of 30&#x000a0;U/kg and 60&#x000a0;U/kg, with a favourable tolerability profile and no new safety concerns over a 5-year treatment period [<xref ref-type="bibr" rid="CR21">21</xref>]. Adult patients who were switched from imiglucerase demonstrated disease stability or improvements after a total of up to 3&#x000a0;years of treatment with taliglucerase alfa [<xref ref-type="bibr" rid="CR19">19</xref>]. In treatment-na&#x000ef;ve paediatric patients who received up to 3&#x000a0;years of treatment with taliglucerase alfa, continuous improvements were observed in visceral and haematologic parameters and biomarkers [<xref ref-type="bibr" rid="CR20">20</xref>]. Paediatric patients who had switched from imiglucerase maintained clinical stability in these parameters during 33&#x000a0;months of treatment [<xref ref-type="bibr" rid="CR20">20</xref>]. Growth inhibition and pubertal delay have been observed in children with GD [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>], and exploratory analyses of growth and development in paediatric patients in the phase 3 taliglucerase alfa studies trended toward improvement in height and weight, progression of pubertal status, and absence of bone crises [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par32">In the pivotal study of taliglucerase alfa in treatment-na&#x000ef;ve adults with Type 1 GD (PB-06-001), the primary endpoint was reduction in spleen volume after 9&#x000a0;months of treatment based on magnetic resonance imaging (MRI) using validated automatic segmentation software in conjunction with a standardized MRI acquisition protocol [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. This primary endpoint was selected in part because changes in spleen volume have been shown to more closely reflect responsiveness to Gaucher-specific therapies than do changes in haematologic parameters. While haematologic parameters are also generally responsive to specific therapy, haemoglobin and platelet counts may be affected by conditions other than GD that may or may not be detected at screening. In addition, while many untreated patients with GD have anaemia, almost all untreated and symptomatic patients with GD have splenomegaly [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. In paediatric studies, use of MRI-based organ volume assessment may not be a first-choice approach because of potential concerns, such as inability to remain still and/or need for sedation during the MRI scan.</p><p id="Par33">The formation of anti-drug antibodies is commonly observed with recombinant therapeutic proteins [<xref ref-type="bibr" rid="CR11">11</xref>] and was observed in clinical studies of taliglucerase alfa but generally did not appear to be associated with the occurrence of AEs or a negative impact on efficacy. The clinical implications of seropositivity for anti-drug antibodies in the absence of AEs are unclear. In addition, comparing the incidence of antibodies to taliglucerase alfa with that of antibodies to other ERT products for GD or other recombinant therapeutic proteins should be approached with caution, as immunogenicity assay results can be highly dependent upon or influenced by extrinsic and intrinsic factors such as the sensitivity and specificity of the assay, assay methodology (including sample handling as well as timing of sample collection), concomitant medication, and underlying disease; hence, comparisons between studies and products may be misleading [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par34">As with other studies of rare diseases, the taliglucerase alfa clinical studies in treatment-na&#x000ef;ve patients with GD were limited by low patient numbers.</p></sec><sec id="Sec13"><title>Conclusions</title><p id="Par35">Treatment with taliglucerase alfa resulted in long-term improvements (treatment-na&#x000ef;ve patients) or stability (patients switched from imiglucerase) in visceral, haematologic, and biomarker parameters. Taliglucerase alfa is the only ERT for GD that was tested prospectively in paediatric-specific studies. Taliglucerase alfa was well tolerated, and AEs were generally mild or moderate in severity and transient in nature. Taken together, the comprehensive data set supports treatment with taliglucerase alfa in adult and paediatric patients with GD who are na&#x000ef;ve to ERT or who have previously been treated with imiglucerase.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AEs</term><def><p id="Par2">adverse events</p></def></def-item><def-item><term>CCL18</term><def><p id="Par3">chemokine C-C motif ligand 18</p></def></def-item><def-item><term>ERT</term><def><p id="Par4">enzyme replacement therapy</p></def></def-item><def-item><term>GD</term><def><p id="Par5">Gaucher disease</p></def></def-item><def-item><term>MN</term><def><p id="Par6">multiples of normal</p></def></def-item><def-item><term>MRI</term><def><p id="Par7">magnetic resonance imaging</p></def></def-item><def-item><term>PK</term><def><p id="Par8">pharmacokinetics</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Editorial and medical writing support was provided by Elizabeth Daro-Kaftan, PhD, of Peloton Advantage, LLC, and was funded by Pfizer. Pfizer and Protalix entered into an agreement in November 2009 to develop and commercialize taliglucerase alfa.</p><sec id="FPar1"><title>Funding</title><p id="Par36">These studies were sponsored by Protalix BioTherapeutics. Pfizer and Protalix entered into an agreement in November 2009 to develop and commercialize taliglucerase alfa.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par37">Data reported in this review article were previously reported in the cited publications. Data sharing is not applicable as no new data sets were generated for the purposes of this article.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>AZ, MW, BH, and GMP participated in the interpretation of the data and edited the manuscript. All authors read and approved the final manuscript. None of the authors received compensation for their contributions to this manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par38">The studies reviewed herein were designed and conducted in compliance with the ethical principles of Good Clinical Practice guidelines in accordance with the Declaration of Helsinki. Investigators obtained informed written consent from each patient and/or parent or guardian before study participation. The study protocols and the informed consent forms were reviewed and approved by the ethics committees/institutional review boards for each study and at each study site.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par39">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par40">Ari Zimran was a consultant for Protalix BioTherapeutics during the course of the taliglucerase alfa studies and has received honoraria from Genzyme/Sanofi, Pfizer, and Shire; his current institution, the Gaucher Clinic, receives grant/research support from Genzyme/Sanofi and Shire. Michael Wajnrajch and Betina Hernandez are employees of Pfizer Inc. Gregory M. Pastores received grant/research support from Actelion, Alexion, Amicus/GSK, BioMarin, Genzyme/Sanofi, Protalix BioTherapeutics/Pfizer, and Shire.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par41">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Zimran A, Elstein D. Gaucher disease and related lysosomal storage diseases. In: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press O, Burns L, et al., editors. Williams Hematology. 9th ed. New York: McGraw-Hill Education; 2016. p. 1121&#x02013;33.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimran</surname><given-names>A</given-names></name><name><surname>Elstein</surname><given-names>D</given-names></name></person-group><article-title>Management of Gaucher disease: enzyme replacement therapy</article-title><source>Pediatr Endocrinol Rev</source><year>2014</year><volume>12</volume><issue>Suppl 1</issue><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">25345089</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Grabowski</surname><given-names>GA</given-names></name><name><surname>Kolodny</surname><given-names>EH</given-names></name><name><surname>Weinreb</surname><given-names>NJ</given-names></name><name><surname>Rosenbloom</surname><given-names>BE</given-names></name><name><surname>Prakash-Cheng</surname><given-names>A</given-names></name><name><surname>Kaplan</surname><given-names>P</given-names></name><etal/><etal/></person-group><person-group person-group-type="editor"><name><surname>Valle</surname><given-names>D</given-names></name><name><surname>Beaudet</surname><given-names>AL</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Antonarakis</surname><given-names>SE</given-names></name><name><surname>Ballabio</surname><given-names>A</given-names></name><etal/><etal/></person-group><article-title>Gaucher disease: phenotypic and genetic variation</article-title><source>The Online Metabolic and Molecular Bases of Inherited Disease</source><year>2010</year><publisher-loc>New York</publisher-loc><publisher-name>McGraw Hill Companies</publisher-name><fpage>1</fpage><lpage>63</lpage></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>NW</given-names></name><name><surname>Brady</surname><given-names>RO</given-names></name><name><surname>Dambrosia</surname><given-names>JM</given-names></name><name><surname>Di Bisceglie</surname><given-names>AM</given-names></name><name><surname>Doppelt</surname><given-names>SH</given-names></name><name><surname>Hill</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease</article-title><source>N Engl J Med</source><year>1991</year><volume>324</volume><fpage>1464</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1056/NEJM199105233242104</pub-id><pub-id pub-id-type="pmid">2023606</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastores</surname><given-names>GM</given-names></name></person-group><article-title>Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease</article-title><source>Curr Opin Investig Drugs</source><year>2010</year><volume>11</volume><fpage>472</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">20336596</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Cerezyme (imiglucerase for injection) [package insert]. Cambridge: Genzyme Corporation; 2011.</mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">VPRIV (velaglucerase alfa for injection) [package insert]. Lexington: Shire Human Genetic Therapies, Inc.; 2015.</mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Elelyso (taliglucerase alfa) for injection [package insert]. New York: Pfizer Labs; 2016.</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaaltiel</surname><given-names>Y</given-names></name><name><surname>Bartfeld</surname><given-names>D</given-names></name><name><surname>Hashmueli</surname><given-names>S</given-names></name><name><surname>Baum</surname><given-names>G</given-names></name><name><surname>Brill-Almon</surname><given-names>E</given-names></name><name><surname>Galili</surname><given-names>G</given-names></name><etal/></person-group><article-title>Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system</article-title><source>Plant Biotechnol J</source><year>2007</year><volume>5</volume><fpage>579</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2007.00263.x</pub-id><pub-id pub-id-type="pmid">17524049</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tekoah</surname><given-names>Y</given-names></name><name><surname>Tzaban</surname><given-names>S</given-names></name><name><surname>Kizhner</surname><given-names>T</given-names></name><name><surname>Hainrichson</surname><given-names>M</given-names></name><name><surname>Gantman</surname><given-names>A</given-names></name><name><surname>Golembo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Glycosylation and functionality of recombinant glucocerebrosidase from various production systems</article-title><source>Biosci Rep</source><year>2013</year><volume>33</volume><fpage>771</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1042/BSR20130081</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabowski</surname><given-names>G</given-names></name><name><surname>Golembo</surname><given-names>M</given-names></name><name><surname>Shaaltiel</surname><given-names>Y</given-names></name></person-group><article-title>Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology [abstract]</article-title><source>Mol Genet Metab</source><year>2014</year><volume>111</volume><fpage>S49</fpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollak</surname><given-names>CE</given-names></name><name><surname>vom Dahl</surname><given-names>S</given-names></name><name><surname>Aerts</surname><given-names>JM</given-names></name><name><surname>Belmatoug</surname><given-names>N</given-names></name><name><surname>Bembi</surname><given-names>B</given-names></name><name><surname>Cohen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease</article-title><source>Blood Cells Mol Dis</source><year>2010</year><volume>44</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.bcmd.2009.09.006</pub-id><pub-id pub-id-type="pmid">19804996</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Refusal of the marketing authorisation for Elelyso (taliglucerase alfa) London, United Kingdom: European Medicine Agency; 2012 [November 22, 2012]. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002250/WC500129076.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002250/WC500129076.pdf</ext-link>. Accessed June 20, 2017.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>JL</given-names></name></person-group><article-title>First plant-made biologic approved</article-title><source>Nat Biotechnol</source><year>2012</year><volume>30</volume><fpage>472</fpage><pub-id pub-id-type="doi">10.1038/nbt0612-472</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimran</surname><given-names>A</given-names></name><name><surname>Brill-Almon</surname><given-names>E</given-names></name><name><surname>Chertkoff</surname><given-names>R</given-names></name><name><surname>Petakov</surname><given-names>M</given-names></name><name><surname>Blanco-Favela</surname><given-names>F</given-names></name><name><surname>Terreros Munoz</surname><given-names>E</given-names></name><etal/></person-group><article-title>Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>5767</fpage><lpage>5773</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-07-366955</pub-id><pub-id pub-id-type="pmid">21900191</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastores</surname><given-names>GM</given-names></name><name><surname>Petakov</surname><given-names>M</given-names></name><name><surname>Giraldo</surname><given-names>P</given-names></name><name><surname>Rosenbaum</surname><given-names>H</given-names></name><name><surname>Szer</surname><given-names>J</given-names></name><name><surname>Deegan</surname><given-names>PB</given-names></name><etal/></person-group><article-title>A phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase</article-title><source>Blood Cells Mol Dis</source><year>2014</year><volume>53</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.bcmd.2014.05.004</pub-id><pub-id pub-id-type="pmid">24950666</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimran</surname><given-names>A</given-names></name><name><surname>Gonzalez-Rodriguez</surname><given-names>DE</given-names></name><name><surname>Abrahamov</surname><given-names>A</given-names></name><name><surname>Elstein</surname><given-names>D</given-names></name><name><surname>Paz</surname><given-names>A</given-names></name><name><surname>Brill-Almon</surname><given-names>E</given-names></name><etal/></person-group><article-title>Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease</article-title><source>Blood Cells Mol Dis</source><year>2015</year><volume>54</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.bcmd.2014.10.002</pub-id><pub-id pub-id-type="pmid">25453586</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimran</surname><given-names>A</given-names></name><name><surname>Duran</surname><given-names>G</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Giraldo</surname><given-names>P</given-names></name><name><surname>Rosenbaum</surname><given-names>H</given-names></name><name><surname>Giona</surname><given-names>F</given-names></name><etal/></person-group><article-title>Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naive patients with Gaucher disease</article-title><source>Am J Hematol</source><year>2016</year><volume>91</volume><fpage>656</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1002/ajh.24369</pub-id><pub-id pub-id-type="pmid">27174694</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastores</surname><given-names>GM</given-names></name><name><surname>Shankar</surname><given-names>SP</given-names></name><name><surname>Petakov</surname><given-names>M</given-names></name><name><surname>Giraldo</surname><given-names>P</given-names></name><name><surname>Rosenbaum</surname><given-names>H</given-names></name><name><surname>Amato</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase</article-title><source>Am J Hematol</source><year>2016</year><volume>91</volume><fpage>661</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1002/ajh.24399</pub-id><pub-id pub-id-type="pmid">27102949</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, et al. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naive or previously treated with imiglucerase. Blood Cells Mol Dis. 2018;68:163-72.</mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Zimran A, Duran G, Giraldo P, Rosenbaum H, Giona F, Petakov M, et al. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naive patients with Gaucher disease. Blood Cells Mol Dis. 2016. [Epub ahead of print].</mixed-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>G</given-names></name><name><surname>Damle</surname><given-names>B</given-names></name><name><surname>Chertkoff</surname><given-names>R</given-names></name><name><surname>Alon</surname><given-names>S</given-names></name></person-group><article-title>Pharmacokinetics of novel plant cell-expressed taliglucerase alfa in adult and pediatric patients with Gaucher disease</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0128986</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0128986</pub-id><pub-id pub-id-type="pmid">26053270</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimran</surname><given-names>A</given-names></name><name><surname>Kay</surname><given-names>A</given-names></name><name><surname>Gelbart</surname><given-names>T</given-names></name><name><surname>Garver</surname><given-names>P</given-names></name><name><surname>Thurston</surname><given-names>D</given-names></name><name><surname>Saven</surname><given-names>A</given-names></name><etal/></person-group><article-title>Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients</article-title><source>Medicine (Baltimore)</source><year>1992</year><volume>71</volume><fpage>337</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1097/00005792-199211000-00002</pub-id><pub-id pub-id-type="pmid">1435229</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zevin</surname><given-names>S</given-names></name><name><surname>Abrahamov</surname><given-names>A</given-names></name><name><surname>Hadas-Halpern</surname><given-names>I</given-names></name><name><surname>Kannai</surname><given-names>R</given-names></name><name><surname>Levy-Lahad</surname><given-names>E</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy</article-title><source>Q J Med</source><year>1993</year><volume>86</volume><fpage>565</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">8255971</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charrow</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>HC</given-names></name><name><surname>Kaplan</surname><given-names>P</given-names></name><name><surname>Kolodny</surname><given-names>EH</given-names></name><name><surname>Mistry</surname><given-names>P</given-names></name><name><surname>Pastores</surname><given-names>G</given-names></name><etal/></person-group><article-title>Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations</article-title><source>J Pediatr</source><year>2004</year><volume>144</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2003.10.067</pub-id><pub-id pub-id-type="pmid">14722528</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabowski</surname><given-names>GA</given-names></name><name><surname>Andria</surname><given-names>G</given-names></name><name><surname>Baldellou</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>PE</given-names></name><name><surname>Charrow</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>IJ</given-names></name><etal/></person-group><article-title>Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements</article-title><source>Eur J Pediatr</source><year>2004</year><volume>163</volume><fpage>58</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/s00431-003-1362-0</pub-id><pub-id pub-id-type="pmid">14677061</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>HC</given-names></name><name><surname>Kacena</surname><given-names>KA</given-names></name><name><surname>Yee</surname><given-names>JD</given-names></name></person-group><article-title>The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis</article-title><source>Arch Pediatr Adolesc Med</source><year>2006</year><volume>160</volume><fpage>603</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1001/archpedi.160.6.603</pub-id><pub-id pub-id-type="pmid">16754822</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Weinreb</surname><given-names>NJ</given-names></name><name><surname>Kaplan</surname><given-names>P</given-names></name><name><surname>Cole</surname><given-names>JA</given-names></name><name><surname>Gwosdow</surname><given-names>AR</given-names></name><name><surname>Hangartner</surname><given-names>T</given-names></name></person-group><article-title>Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults</article-title><source>Blood Cells Mol Dis</source><year>2011</year><volume>46</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.bcmd.2010.10.011</pub-id><pub-id pub-id-type="pmid">21112800</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracoud</surname><given-names>L</given-names></name><name><surname>Ahmad</surname><given-names>H</given-names></name><name><surname>Brill-Almon</surname><given-names>E</given-names></name><name><surname>Chertkoff</surname><given-names>R</given-names></name></person-group><article-title>Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model</article-title><source>Blood Cells Mol Dis</source><year>2011</year><volume>46</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.bcmd.2010.10.009</pub-id><pub-id pub-id-type="pmid">21084202</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Fost</surname><given-names>M</given-names></name><name><surname>Hollak</surname><given-names>CE</given-names></name><name><surname>Groener</surname><given-names>JE</given-names></name><name><surname>Aerts</surname><given-names>JM</given-names></name><name><surname>Maas</surname><given-names>M</given-names></name><name><surname>Poll</surname><given-names>LW</given-names></name><etal/></person-group><article-title>Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis</article-title><source>Blood</source><year>2006</year><volume>108</volume><fpage>830</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-12-5072</pub-id><pub-id pub-id-type="pmid">16527890</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charrow</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>HC</given-names></name><name><surname>Kaplan</surname><given-names>P</given-names></name><name><surname>Kolodny</surname><given-names>EH</given-names></name><name><surname>Mistry</surname><given-names>P</given-names></name><name><surname>Pastores</surname><given-names>G</given-names></name><etal/></person-group><article-title>The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease</article-title><source>Arch Intern Med</source><year>2000</year><volume>160</volume><fpage>2835</fpage><lpage>2843</lpage><pub-id pub-id-type="doi">10.1001/archinte.160.18.2835</pub-id><pub-id pub-id-type="pmid">11025794</pub-id></element-citation></ref></ref-list></back></article>